Jacobus Pharmaceutical Company, Inc.

5 articles about Jacobus Pharmaceutical Company, Inc.

• Catalyst Pharmaceuticals Announces Filing of Patent Infringement Actions Against Jacobus Pharmaceuticals and PantherRx

  10/19/2020

  Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it has filed a lawsuit in the U.S. District Court for New Jersey against Jacobus Pharmaceuticals, Inc. (Jacobus), and a lawsuit in the U.S. District Court for the Western Di

• 

  Judge Sides with FDA, Jacobus Pharma in Fight Over LEMS Treatment Approval

  9/30/2020

  Catalyst Pharmaceuticals is reeling this morning after a federal judge dismissed the company’s lawsuit against the U.S. Food and Drug Administration regarding the approval of a rival drug for a rare autoimmune disease from New Jersey-based Jacobus Pharmaceutical.

• Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration

  6/12/2019

  Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act

• 

  Catalyst Shares Plunge Following FDA Approval of Rival LEMS Drug

  5/7/2019

  The Jacobus LEMS Drug was approved for pediatric patients. However, the approval was based on results from a study of adult patients, which means that doctors could opt to prescribe this medication for adult LEMS patients.

• Family-Run Drugmaker Jacobus Pharma Fights to Stay Alive in the Martin Shkreli Era of High Priced Drugs

  4/5/2016